News 2023-09-20
Porton Gets Improved in the 2023 S&P Global ESG Score
Porton Pharma Solutions Ltd. is glad to announce that it scored 38 (out of 100) in the 2023 S&P Global Corporate Sustainability Assessment reflecting an improvement of 9 points based on the 2023 methodology over the last year, where scores in all the three dimensions getting improved and exceeding the industry average. (CSA Score as of 25/08/2023).
Porton continues to gain ground in its environmental, social, and governance initiatives. In 2023, Porton establishes a top-down ESG governance structure, which includes Board Strategy and ESG Committee, ESG Executive Committee and ESG Working Team, to ensure the implementation of responsibilities and management measures. Meanwhile, Porton has identified 19 ESG high material issues and will further address and respond to these issues and enhance ESG performance.
Governance |
Social |
Environmental |
Business ethics Operational compliance |
R&D and innovation IP protection Product quality and safety Customer service Data and information security Digitalization Diversity, equity and inclusion Occupational health and safety Human capital development Supply chain security Access to healthcare and wellbeing Green chemistry Community communication and development |
Environmental policy and management systems Wastewater management Waste management Climate change |
For Porton, improving ESG governance and performance is a continuous evolutionary process. We will always be committed to cooperating with all stakeholders to achieve sustainable development.
Others
More
News 2025-04-16
Porton Advanced's End-to-End CDMO Solutions Accelerates IND Approval of Tasly's Innovative Dual-Targeting CAR-T Therapy
April 12, 2025 - Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD’s Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) (Approval No.: 2025LP01030). This breakthrough CAR-T therapy is indicated for recurrent glioblastoma (GBM).

News 2025-04-11
Porton Newsletter - Q1 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities